157618-75-2

Upstream product

• 16338-48-0 L-allylglycine 
• 1247052-91-0 S-(R)-1-[(3S,9S,14aR)-9-benzyl-6,6-dimethyl-1,4,7,10-tetraoxotetradecahydropyrrolo[1,2-a][1,4,7,10]tetraazacyclododecin-3-yl]-7-(tert-butyldimethylsilyloxy)-6-oxooctan-3-yl O-ethyl carbonodithioate 
• 1247052-65-8 (-)-(3S,9S,14aR)-9-benzyl-3-(but-3-enyl)-6,6-dimethyldecahydropyrrolo[1,2-a][1,4,7,10]tetraazacyclododecine-1,4,7,10-tetraone 
• 1247052-63-6 C₃₃H₅₀N₄O₇ 
• 92136-57-7 (S)-2-tert-butoxycarbonylamino-hex-5-enoic acid methyl ester 
• 1247053-01-5 (-)-(3S,9S,14aR)-9-benzyl-3-[(R)-7-(tert-butyldimethylsilyloxy)-6-oxooctyl]-6,6-dimethyldecahydropyrrolo[1,2-a][1,4,7,10]tetraazacyclododecine-1,4,7,10-tetraone 
• 874384-02-8 (S)-2-(dibenzylamino)-6-oxohexanoic acid benzyl ester 
• 874384-03-9 (E)-(S)-2-Dibenzylamino-6-methoxy-hex-5-enoic acid benzyl ester 
• 874384-01-7 benzyl (S)-2-(dibenzylamino)pent-4-enoate 
• 850209-98-2 (S)-2-dibenzylamino-5-hydroxypentanoic acid benzyl ester 
• 874384-22-2 (R)-1-{(S)-2-[2-((2S,9R)-2-Amino-9-hydroxy-8-oxo-decanoylamino)-2-methyl-propionylamino]-3-phenyl-propionyl}-pyrrolidine-2-carboxylic acid 
• 850209-99-3 2-dibenzylamino-5-oxo-pentanoic acid benzyl ester 
• 167905-35-3 (S)-2-dibenzylaminopentanedioic acid dibenzyl ester 
• 71989-31-6 (R)-Pyrrolidine-1,2-dicarboxylic acid 1-(9H-fluoren-9-ylmethyl) ester 

Downstream Products

• 202869-98-5 cyclo[2-aminoisobutyryl-(S)-phenylalanyl-(R)-prolyl-(2S,8R,9R)-2-amino-8,9-dihydroxydecanoyl] 
• 104849-05-0 cyclo[2-aminoisobutyryl-(S)-phenylalanyl-(R)-prolyl-(S)-2-aminosuberoyl-] 
• 4254-88-0 (2S)-L-α-Aminosuberic acid 

Relevant academic research and scientific papers

Flexible synthesis and evaluation of diverse anti-apicomplexa cyclic peptides

A modular approach to synthesize anti-Apicomplexa parasite inhibitors was developed that takes advantage of a pluripotent cyclic tetrapeptide scaffold capable of adjusting appendage and skeletal diversities in only a few steps (one to three steps). The diversification processes make use of selective radical coupling reactions and involve a new example of a reductive carbon-nitrogen cleavage reaction with SmI2. The resulting bioactive cyclic peptides have revealed new insights into structural factors that govern selectivity between Apicomplexa parasites such as Toxoplasma and Plasmodium and human cells.

CYCLIC PEPTIDES WITH AN ANTI-PARASITIC ACTIVITY

The present invention relates to a method for preparing a cyclic peptide with antiparasite activity and anticancer activity. The invention also relates to this peptide as an antiparasite agent, for example in the treatment of toxoplasmosis and as an antic

Synthesis of 2-amino-8-oxodecanoic acids (Aodas) present in natural hystone deacetylase inhibitors

Differently substituted 2-amino-8-oxodecanoic acids (Aodas), present in naturally occurring inhibitors of hystone deacetylase (HDAC), have been prepared using a convergent approach. The configuration in position 2 was derived from enantiomerically pure allylglycine or glutamic acid, whereas the stereochemistry of the substituent in position 9 derived from lactic acid or glyceraldehyde derivatives. Starting from allylglycine, (S)-Aodas, protected at the nitrogen as Boc or Fmoc, were obtained in four steps in about 30% overall yield. These products have been used to prepare a simplified analogue of a natural cyclic tetrapeptide HDAC inhibitor by SPPS.